The Role of Celecoxib for Treatment of Refractory Nocturia Caused by Benign Prostatic Hyperplasia | ||
| Medical Journal of Babylon | ||
| Article 1, Volume 11, Issue 2, June 2014, Pages 428-436 | ||
| Authors | ||
| Mohammed Bassil Ismail; Adil Hefdhi Al.soufi; Hasanin Farhan Hasan | ||
| Abstract | ||
| Objective: Nocturia is a well-recognized symptom in patient with benign prostatic hyperplasia ( BPH), which is commonly treated by alpha- blocker and/ or 5 alpha - reductase inhibitors. However, the effectiveness of these drugs for nocturia has been reported to be only 25%- 39%. The aim of this study was to investigate the efficacy of celecoxib, a cyclooxygenase -2 inhibitor, in the treatment of patient with BPH complaing of nocturia. Patients and methods: A prospective study of 50 men with signs tract symptoms and BPH of refractory nocturia to alpha- blocker and/ or 5 alpha reductase inhibitor more than two episodes of nocturia per night were involved for nocturia. Although these patients had received standard drug therapy for more than one month , they had still three or more episodes of nocturia. The patients took a single dose of 100 mg of celecoxib at night prior to sleep. and 2 week after the initiation of this therapy, the effects of this treatment were assessed by frequency chart and a questionnaire. Results: In the questionnaire ,32 of 50 patients (64%) had an excellent response with celecoxib treatment than previous treatments, 14 of 50 patients (24%) had an improvement with celecoxib treatment than previous treatments, 4 of 50 patients (8%) had no response with celecoxib treatment, Nocturnal frequency showed a statistically significant reduction from, baseline after two weeks treatment with celecoxib (P < 0.01), International Prostate Symptom Score( IPSS) showed a statistically significant reduction from baseline after two weeks treatment with celecoxib (P < 0.01), peak flow rate showed a statistically no response from baseline after two weeks treatment with celecoxib (P < 0.05). Conclusion: Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia. The results suggest a novel treatment option for this common condition. | ||
| Keywords | ||
| nocturia; celecoxib; benign prostatic hyperplasia | ||
|
Statistics Article View: 32 PDF Download: 17 |
||